4.15

1.97% 0.08

After Hours: 4.04 -0.11 -2.65%

Briacell Therapeutics Corp (BCTX)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Briacell Therapeutics Corp stock is traded at $4.15, with a volume of 203.41K. It is up +1.97% in the last 24 hours and down -3.94% over the past month. BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Previous Close:

$4.07

Open:

$4.15

24h Volume:

203.41K

Relative Volume:

1.09

Market Cap:

$30.09M

Revenue:

Net Income/Loss:

$-29.96M

P/E Ratio:

-0.1502

EPS:

-27.6253

Net Cash Flow:

$-31.64M

1W Performance:

+3.23%

1M Performance:

-3.94%

6M Performance:

-57.78%

1Y Performance:

+21.35%

1-Day Range:

$4.01

$4.21

1-Week Range:

$3.96

$4.25

52-Week Range:

$0.61

$14.68

Briacell Therapeutics Corp Stock (BCTX) Company Profile

Name

Briacell Therapeutics Corp

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

(604) 921-1810

Address

3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER

Employee

Twitter

Next Earnings Date

2026-06-15

Latest SEC Filings

BCTX's Discussions on Twitter

Compare BCTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BCTX Briacell Therapeutics Corp	4.15	29.51M	0	-29.96M	-31.64M	-27.63
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Briacell Therapeutics Corp Stock (BCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-14-22	Initiated	H.C. Wainwright	Buy

Briacell Therapeutics Corp Stock (BCTX) Latest News

09:09 AM

BriaCell receives FDA green light to advance breast cancer immunotherapy | 2026-05-06 | Investing News - Stockhouse

09:09 AM

07:44 AM

BriaCell receives FDA clearance for breast cancer therapy trial - Investing.com

07:44 AM

07:32 AM

FDA clears BriaCell's personalized breast cancer study to start - Stock Titan

07:32 AM

07:30 AM

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer - GlobeNewswire

07:30 AM

04:08 AM

MSN Money - MSN

04:08 AM

Apr 27, 2026

BriaCell Announces Six Clinical Data Presentations at ASCO 2026 - The Manila Times

Apr 27, 2026

Six metastatic breast cancer studies put BriaCell on ASCO's 2026 agenda - Stock Titan

Apr 27, 2026

Apr 26, 2026

BriaCell to implement 1-for-10 reverse stock split to maintain Nasdaq listing - MSN

Apr 26, 2026

Apr 23, 2026

BrianCell Therapeutics drops 10%, prices $30M offering at $5.59 per unit - MSN

Apr 23, 2026

BriaCell (BCTXL) Q4 Outlook Earnings ReportHigh Volatility - Xã Thanh Hà

Apr 23, 2026

BCTX (BriaCell Therapeutics Corp.) posts narrower than expected Q1 2026 loss, shares rise 1.76% today.Hot Community Stocks - Cổng thông tin điện tử Tỉnh Sơn La

Apr 23, 2026

BCTXZ (BriaCell) outlines late-stage oncology pipeline progress as key focus in latest quarterly earnings release.Crowd Consensus Signals - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 23, 2026

BriaCell Shares Slide 22% After Announcing Dilutive Public Offering - MSN

Apr 23, 2026

Apr 21, 2026

BriaCell Therapeutics : Investor Presentation (2026Apr21 Investor Presentation) - marketscreener.com

Apr 21, 2026

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models - The Manila Times

Apr 21, 2026

BriaCell presents phase 3 breast cancer quality of life data at AACR - Investing.com India

Apr 21, 2026

Apr 20, 2026

BriaCell Therapeutics : Investor Presentation (2026Apr20 Investor Presentation) - marketscreener.com

Apr 20, 2026

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting - GuruFocus

Apr 20, 2026

BriaCell presents phase 3 breast cancer quality of life data at AACR By Investing.com - Investing.com South Africa

Apr 20, 2026

What should I do with BriaCell (BCTX) stock today (Pressure Mounts) 2026-04-20Retail Trader Ideas - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting - Investing News Network

Apr 20, 2026

Late-stage breast cancer patients preserved quality of life in trial - Stock Titan

Apr 20, 2026

Apr 17, 2026

BriaCell: Advancing Toward Approval with Late-Stage Breast Cancer Immunotherapy - The Globe and Mail

Apr 17, 2026

Apr 14, 2026

Certain Performance Share Units of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 15-APR-2026. - marketscreener.com

Apr 14, 2026

Certain Options of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 15-APR-2026. - marketscreener.com

Apr 14, 2026

Certain Warrants of BriaCell Therapeutics Corp. are subject to a Lock-Up Agreement Ending on 15-APR-2026. - marketscreener.com

Apr 14, 2026